Search

Search Constraints

You searched for: Author/Creator Kost, James

Search Results

1. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Issue 11 (13th October 2020)

2. FTS3‐01‐05: FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE‐3 TRIAL OF VERUBECESTAT IN PRODROMAL AD. (1st July 2019)

3. O3‐10‐02: VERUBECESTAT‐INDUCED BRAIN VOLUME LOSS OCCURS RAPIDLY AND ONLY IN AMYLOID‐ENRICHED BRAIN REGIONS IN EPOCH, A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE PATIENTS. (1st July 2019)

4. P1‐042: NEUROFIBRILLARY TANGLE IMAGING WITH [18F]MK‐6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE PATIENTS. (1st July 2019)

5. P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS. (1st July 2019)

6. P2‐014: Relationship Between Volumetric MRI Parameters, APOE4 and MMSE Status at Baseline in The Verubecestat (MK‐8931) Mild to Moderate Alzheimer's Disease Phase 2/3 Trial. (1st July 2016)

8. P4‐013: DESIGN OF A PHASE‐3 TRIAL (APECS) TO EVALUATE THE BACE INHIBITOR VERUBECESTAT IN PRODROMAL AD. (1st July 2006)

9. P4‐040: Does Regional Amyloid Burden Impact Domain‐Specific Cognitive Impairment?. (1st July 2016)

10. P4‐380: BACE Inhibitor Verubecestat (MK‐8931): Baseline Characteristics for Participants Enrolled in the Phase II/III Epoch Alzheimer'S Disease Trial. (1st July 2016)